This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Metabolic syndrome, a cluster of cardiovascular risk factors, including insulin resistance, increased abdominal girth, hypertension and dyslipidemia, is thought to be a chromic inflammatory state. TNF-alpha is an inflammatory cytokine that may downregulate adiponectin and contribute to insulin resistance.
The aims of the study are to determine the short-term effects of TNF-alpha blockade with Etanercept on inflammatory markers, adiponectin, and insulin sensitivity in patients with metabolic syndrome. The hypothesis is that TNF-alpha blockade will reduce measures of inflammation, raise adiponectin and thus improve insulin sensitivity in this patient population.
Showing the most recent 10 out of 945 publications
